Also, other potential opportunities for targeted drug development in IBD include specific chemical inhibitors of SK, specific small molecule inhibitors directed against catalytic subunits of the immunoproteasome, and dual inhibitors of the STAT3 and NF-κB signal transduction systems (Figure 2). Here, NFKB1 is linked to inflammatory bowel disease.